• Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
  

PubMed=8632910
Pocard M., Chevillard S., Villaudy J., Poupon M.-F., Dutrillaux B., Remvikos Y.
Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation.
Oncogene 12:875-882(1996)

PubMed=9989828; DOI=10.1038/sj.onc.1202336
Soulie P., Poupon M.-F., Remvikos Y., Dutrillaux B., Muleris M.
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
Oncogene 18:775-781(1999)

PubMed=17339891; DOI=10.1038/sj.bjc.6603639; PMCID=PMC2360080
Giovannetti E., Backus H.H.J., Wouters D., Ferreira C.G., van Houten V.M.M., Brakenhoff R.H., Poupon M.-F., Azzarello A., Pinedo H.M., Peters G.J.
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Br. J. Cancer 96:769-775(2007)

PubMed=18600534; DOI=10.1080/15257770802145512
Giovannetti E., Backus H.H.J., Wouters D., Peters G.J.
Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
Nucleosides Nucleotides Nucleic Acids 27:740-745(2008)